Pharmacogenetics: ethical problems and solutions

  title={Pharmacogenetics: ethical problems and solutions},
  author={Alasdair M. Breckenridge and Klaus Lindpaintner and Peter Lipton and Howard L. McLeod and Mark a. Rothstein and Helene Wallace},
  journal={Nature Reviews Genetics},
Regulators, drug companies, academic scientists, bioethicists, clinicians and, increasingly, the general public are starting to realize that pharmacogenetics (PGx) will probably have a huge impact on the way in which we treat both common and rare diseases. But how much thought has gone into the ethical issues that the incorportation of phamacogenetic testing into drug discovery, prescription and use will entail? It seems that “quite a bit” is the answer, as the diverse viewpoints of… 

Applying Existing Ethical Principles to Personal Medicine

Three topics with ethical implications: (1) privacy concerns, (2) economic considerations, and (3) potential malpractice litigation, are discussed along with the application of existing ethical principles to each.

Pharmacogenetics in Europe: Barriers and Opportunities

It seems that one key aspect where policy can affect the clinical uptake of PGx is via sustaining large-scale industry-academia collaborations for developing and proving the utility ofPGx diagnostics.

Clinical implementation of pharmacogenetics: a nonrepresentative explorative survey to participants of WorldPharma 2010.

The results of an explorative nonrepresentative survey are described that attempted to evaluate the perceived status quo of, and the obstacles facing, PGx implementation in clinical practice in countries with emerging and developing economies versus countries with advanced economies.

Pharmacogenetics: Future of the drug therapy

Pharmacogenetics, which deals with the genetic basis underlying variable drug response, offers the potential of individualizing drug therapy, and through optimizing efficacy and minimizing toxicity it increases the possibility for a wide range of diseases to be cured and controlled.

Personalized medicine: how much can we afford? A bioethics perspective.

This paper tries to show that from a bioethics perspective public health practices and personalized medicine are not mutually exclusive, and a scenario that seeks to integrate both concepts in a complementary fashion may maximize the benefit for both individuals and the community.

Genetic diversity and new therapeutic concepts

  • B. Shastry
  • Biology, Medicine
    Journal of Human Genetics
  • 2005
AbstractThe differences in medicinal drug responses among individuals had been known for quite some time. Some patients exhibit a life-threatening adverse reaction while others fail to show an

Ethical aspects on rare diseases.

This chapter addresses problems related to diagnosis and some ethical aspects of newborn screening, prenatal, pre-implantation diagnosis and reference centers, as well as some conditions that should be met by the persons and institutions performing such tasks.

Pharmacogenomics: Challenges and Opportunities

This review will outline progress in the field by describing mechanisms underlying variable drug responses, the potential role of genetic factors in their causes, and contemporary and evolving approaches to identifying these genetic factors.

Attitudes of Health Care Professionals Toward Pharmacogenetic Testing

The findings demonstrate the existence and seriousness of several challenges pertaining to pharmacogenetic applications in the clinical setting and further training and education are needed for health care professionals, since they are the ones who will most probably request these tests in the near future.



Pharmacogenetics goes genomic

It seems increasingly likely that investment in Pharmacogenetics might be the most effective strategy for rapidly delivering the public health benefits that are promised by the Human Genome Project and related endeavours.

Inheritance and drug response.

The underlying message is that inherited variations in drug effect are common and that some tests that incorporate pharmacogenetics into clinical practice are now available, with many more to follow.

The genetic basis of variability in drug responses

The concept that genetic variants might determine much of this variability in drug response is discussed, and an algorithm is proposed to enable further evaluation of the benefits and pitfalls of this enticing possibility.

Pharmacogenetics and adverse drug reactions

Characterization of the common genetic defect in humans deficient in debrisoquine metabolism

It is shown that poor meta-bolizers have negligible amounts of the cytochrome P450 enzyme P450dbl, providing a molecular explanation for one of man's most commonly defective genes.

Identification of the primary gene defect at the cytochrome P450 CYP2D locus

The identification of the primary mutation responsible for this metabolic defect and the development of a simple DNA-based genetic assay are reported to allow both the identification of most individuals at risk of drug side-effects and clarification of the conflicting reports on the association of this polymorphism with cancer susceptibility.

Pharmacogenetics of mephenytoin: A new drug hydroxylation polymorphism in man

The co-inheritance of extensive and poor hydroxylation of mephenytoin and nirvanol, respectively, represents a new drug hydroxymation polymorphism in man.

Molecular mechanism of slow acetylation of drugs and carcinogens in humans.

A simple DNA amplification assay is developed that allows the predictive genotyping of more than 95% of slow and rapid acetylator alleles and the identification of individuals at risk.

The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

The present data suggest that the incidence of the Leu359 allelic variant of CYP2C9 may account for the occurrence of poor metabolizers of tolbutamide.

Identification of a new genetic defect responsible for the polymorphism of (S)-mephenytoin metabolism in Japanese.

A new mutation is identified in Japanese poor metabolizers, consisting of a guanine to adenine mutation at position 636 of exon 4 of CYP2C19, which creates a premature stop codon.